PD-152 Identification of patients potentially benefitting from concomitant EGF-R inhibition and chemotherapy: Challenge trial: Erlotinib followed by gemcitabine/cisplatin +/− erlotinib induction in patients with NSCLC IIIA (N2)/IIIB (N3) monitored by microarray-analyses

The file will be sent to you via the Telegram messenger. It may take up to 1-5 minutes before you receive it.

Note: Make sure you have linked your account to Z-Library Telegram bot.

The file will be sent to your Kindle account. It may take up to 1–5 minutes before you receive it.

Please note: you need to verify every book you want to send to your Kindle. Check your mailbox for the verification email from Amazon Kindle.